Biopharma companies generate a lot of proprietary data. But as the Benchling State of Tech in Biopharma report indicates, large and small Biopharma companies struggle to successfully leverage ML solutions in their discovery pipelines. At Ensemble, we’re meeting this industry need with scalable technology that automates data mapping and integration. Our “Dark Matter” solution plugs into existing data pipelines to uncover meaningful patterns and insights across complex data sets. The result? A machine learning stack that measurably accelerates decision-making and innovation. The proof? Consider our case study focused on the open-source Kinase Cancer Inhibitor dataset. Dark Matter demonstrably boosted the performance of linear and non-linear classification algorithms in identifying top-performing inhibitors. (Link: https://buff.ly/3ZKvi3a ) Better data = Better predictions. Get in touch for a demo or to learn more. https://buff.ly/3BbNKbp #BioPharma #AIReady #DrugDiscovery #Innovation#DataScience
Ensemble的动态
最相关的动态
-
??? Join our webinar co-hosted with Accenture: New technologies to accelerate ADC design! Antibody-drug conjugates (ADCs) are transforming cancer therapy, with 15 approved drugs on the market — but over 100 discontinued programs highlight the complexity of ADC design. How can we overcome these challenges to accelerate development? ??? When: December 12, 2024 - 3pm (GMT) ??? Speakers: Eleni Tokali (Host) Daniel Veres MD PhD (Co-founder & CSO, Turbine) Hassan Naseri (Scientific & Next Gen. Computing Lead, Accenture) ?? Topics: 1?? Overview of the ADC market and challenges of ADC design 2?? How can simulations help in understanding payload response and matching them to the right patients? 3?? How can AI-driven tools help in designing cleavable linkers for ADCs? Don’t miss this opportunity to explore the future of ADCs! https://lnkd.in/d_ifg_Kb
-
???????????? ?????????????????????????????? ???????????? $??????, ???????????????? ???????? ?????????????????????? Tracer Biotechnologies has raised a $10 million Series A round to advance its technology that’s designed to monitor circulating tumor DNA in cancer patients over … https://lnkd.in/djkHFmV2
-
On the latest episode of 'Product Led Growth Leaders', hosted by Thomas Watkins, Saurabh Jain, Executive Chairman of Opyl, discusses how our custom LLM turns vast amounts of unstructured data into structured, actionable insights, providing precise probabilities for trial success. "The next step we’re thinking about after we’re done with this is to delve into generative AI. I’ve got small cell lung cancer, I’m in stage four, here’s my therapy, here’s my mode. Build a clinical trial protocol that’s most likely to succeed based on all the other cancer trials and all other small cell cancer trials." ?? Tune in now: https://lnkd.in/gxCkFVbd Marketing, investor, and guest appearance enquiries: [email protected] Book a demo: https://lnkd.in/g9rJtUBm #Clinicaltrials #AI #biotech #pharmaceuticals #clinicalresearch #medicalresearch #medtech #healthtech #generativeai
-
-
Vice-President of the Spanish Biotechnology Companies Association (ASEBIO) 2020/2024. CEO and partner at A4cell
?? Enhance and Refine Your Spheroid Assays with SPAchip! ?? At ARRAYS FOR CELL NANODEVICES, SL - A4CELL, we're pushing the boundaries of drug discovery by leveraging 3D cancer models and spheroid cultures. Our Cell-LAB services powered by #SPAchip allow for the precise monitoring of spheroid cultures, ensuring consistent, reproducible results. ?? Whether you’re in the field of cancer research or drug development, our cutting-edge technology can help boost the confidence in your cell-assay workflows. Say goodbye to variability and hello to reliable, high-quality data! ?? Ready to empower your drug discovery pipeline? Let’s talk about how #SPAchip can transform your 3D models. #DrugDiscovery #3DCellModels #CancerResearch #CellAssays #SPAchip #A4cell #InnovativeTechnology #Spheroids
-
-
Unlocking the Power of ctDNA Analysis for Streamlined Oncology Drug Development. Discover how Simsen Diagnostics can revolutionize your clinical trials. Our cutting-edge ctDNA technology offers: - Earlier detection of treatment response - More precise patient stratification - Reduced costs and accelerated timelines By leveraging minimally invasive liquid biopsies, we're helping pharma companies bring life-saving cancer therapies to market faster. Want to learn more? Follow us on Simsen Diagnostics LinkedIn page. Or - drop us a message on [email protected] to receive our White Paper. Don't miss this opportunity to stay ahead in the competitive landscape of oncology drug development! #CancerResearch #Oncology #ClinicalTrials #Biotech #SimsenDiagnostics #ctDNA #InnovationInDiagnostics
-
“Targeted radiopharmaceuticals are emerging as a new favorite among big pharma buyers and investors” is the verdict from Melanie Senior in her recent article for #NatureBiotechnology (Springer Nature Group). In this comprehensive and well-researched feature, she gives a knowledgeable overview of the fashionable nuclear medicine field, referencing also?Pentixapharm’s CXCR4-based radiopharmaceutical program for CNS lymphoma. ? You can read the complete article right now just by clicking below!??? ? #radiopharmaceuticals #nuclearmedicine #theranostics #innovation #CXCR4
Biopharma reporter for Nature Biotechnology, Evaluate Pharma, IN VIVO. Science strategy writer for biopharma firms
Move over, antibody–drug conjugates. Targeted radiopharmaceuticals are the new favorite. Here's what radiopharma leaders are saying: “You get a level of information you can’t get with any other modality. You can’t quantify where your ADCs [antibody–drug conjugates] or your CAR-Ts (chimeric antigen receptor-T cells) are." Alpha radiation is so potent that only a handful of molecules need reach the cancer cell to eliminate it, opening up “a crazy number of potential molecular targets,” including low-expression targets. “You have a very precise warhead that finds the tumor wherever it is. That could get into the mainstream." Still, "everyone is still learning; we need more data" “This is still a young industry. There is a lot more to come." Read the full piece at https://lnkd.in/eFFR888i
-
Biopharma reporter for Nature Biotechnology, Evaluate Pharma, IN VIVO. Science strategy writer for biopharma firms
Move over, antibody–drug conjugates. Targeted radiopharmaceuticals are the new favorite. Here's what radiopharma leaders are saying: “You get a level of information you can’t get with any other modality. You can’t quantify where your ADCs [antibody–drug conjugates] or your CAR-Ts (chimeric antigen receptor-T cells) are." Alpha radiation is so potent that only a handful of molecules need reach the cancer cell to eliminate it, opening up “a crazy number of potential molecular targets,” including low-expression targets. “You have a very precise warhead that finds the tumor wherever it is. That could get into the mainstream." Still, "everyone is still learning; we need more data" “This is still a young industry. There is a lot more to come." Read the full piece at https://lnkd.in/eFFR888i
-
?? ??????????: ?????????????? ???? ?????? ??????????????????????! ?? At Vivia, we specialize in preclinical and translational evaluations of Antibody-Drug Conjugates (ADCs). ? ?????????????????? ????????????????????: Collaborated on over 20 ADCs across various cancer types. ? ???????????????????? ????????????????: Our assays capture pharmacological profiles in real patient samples, preserving native microenvironments. ? ?????? ??????????????: Identify critical data points for target expression, selectivity, and toxicity. ? ???????????????????????????? ????????????: Measure effects directly in normal bone marrow samples for better in vivo replication. Let’s connect to enhance your ADC development and drive successful clinical studies! ?? Schedule a meeting with our team: https://lnkd.in/g-J9xBPm ?? For custom assays in Hematologic Malignancies, click here: https://lnkd.in/gq4N5YRs ??For custom assays in Solid Tumor, visit our webpage https://lnkd.in/dC5z4jeV #ADC #CancerResearch #TranslationalMedicine #ClinicalDevelopment #Innovation #ViviaBiotech
-
-
?? Revolutionizing Cell Analysis ?? In the fast-paced world of cell analysis, @ThinkCyte VisionSort? platform is setting a new standard. By combining Ghost Cytometry? with AI-driven classification, VisionSort offers a groundbreaking approach to cell sorting. ?? Why it matters: · Label-free analysis: Analyze and sort cells without fluorescent markers, preserving their natural state. · AI-powered precision: Identify unique cell populations with high accuracy. · High throughput: Sort up to 3,000 cells/second while maintaining cell viability. Whether it's cell therapy R&D, drug discovery, or disease profiling, VisionSort opens doors to novel insights and transformative discoveries. ?? ?? Curious to learn more? Read our article here: https://lnkd.in/eah37PNi #ThinkCyte #Cellsorting #DrugDiscovery #CellTherapy #Oncology
-
